SURROZEN INC

SRZNNASDAQ

🏆 #3257 by market capUS Equity

$31.83▲ $2.34 (+7.35%)

Market closed · at close

🔔

Track SRZN

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.3%

7d▲ 96.2%

14d▲ 87.8%

30d▲ 43.5%

ytd▲ 42.2%

1y▲ 165.7%

🏦Market Cap

$370M

Small Cap

📈Revenue Growth (YoY)

-8.8%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

30.2x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $31.43 – $32.30
52-Week Range: $11.39 – $37.83
Volume: $2.60B
Avg Volume: $1.90B
Shares Outstanding: 11.6M
Next Earnings: Dec 13, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $5M
P/E Ratio: —
P/S Ratio: 30.2x
EPS (TTM): $-35.79
Dividend Yield: —
Dilution (1yr): +178.9%

Why Investors Own SRZN

✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
✓Healthy economics — 80% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SURROZEN INC

SRZN

Financial Trends

Revenue

$3M▼ −67.4% YoY

Gross Margin

84.6%▼ −15.4% YoY

Operating Income

−$42M▲ +64.8% YoY

Free Cash Flow

−$30M▲ +72.0% YoY

Shares Outstanding

9.1M▲ +178.9% YoY

Net Cash

$83M▲ +$57M YoY

StockOtter · stockotter.space

About SURROZEN INC

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

🦦